Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Myers Squibb Company

https://www.bms.com/

Latest From Bristol Myers Squibb Company

Hits, Misses & Key Firsts For EMA’s PRIME Scheme

The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.

Europe Research & Development

Exec Chat: Dexcom’s CEO Bullish On Year Ahead With G7 CGM Launch, Dexcom One CGM Expansion

In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.

Business Strategies Diabetic Care

Big Year For UCB As Bimzelx Awaits US Green Light

The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.

Immune Disorders Approvals

J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year Ahead

The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abraxis BioScience, Inc.
    • AbVitro, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Adnexus Therapeutics, Inc.
    • Allied-Bristol Life Sciences, LLC
    • Amira Pharmaceuticals, Inc.
    • Amylin Pharmaceuticals, Inc.
    • Avila Therapeutics, Inc.
    • Bristol-Myers Company
    • Bristol-Myers K.K.
    • Bristol-Myers Squibb
    • Cardioxyl Pharmaceuticals
    • Celgene Corporation
    • Cormorant Pharmaceuticals
    • Delinia, Inc.
    • EngMab AG
    • Flexus Biosciences, Inc.
    • Gloucester Pharmaceuticals, Inc.
    • ißeCa Therapeutics
    • IFM Therapeutics
    • Impact Biomedicines, Inc.
    • Inhibitex, Inc.
    • iPierian Inc.
    • Juno Therapeutics, Inc.
    • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
    • JW Biotechnology (Shanghai) Co., Ltd
    • Kosan
    • Medarex, Inc.
    • Padlock Therapeutics, Inc.
    • Pharmion Corporation
    • Quanticel Pharmaceuticals, Inc.
    • Receptos, Inc.
    • RedoxTherapies, Inc.
    • Westwood-Squibb Pharmaceuticals
    • X-BODY, Inc.
    • ZymoGenetics, Inc.
    • Forbius
    • MyoKardia Inc.
UsernamePublicRestriction

Register